



Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

10-29-2026 at 4:05 PM EDT

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.

Poster Presentations

Title: Selective targeting of integrins $\alpha v \beta 8$ and $\alpha v \beta 1$ improves anti-tumor responses mediated by immune checkpoint inhibition

Poster: 615
Presenter: Nika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute
Date: Friday, November 6, 2026, 12:15 – 1:45 p.m. and 5:30 – 7:30 p.m. Mountain Time
Location: North Building - Lower Level - Exhibition Halls 4-6

*The above presentation includes results that were obtained under a collaboration agreement between the National Cancer Institute and Pliant Therapeutics.

Title: Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced solid tumors receiving dual $\alpha v \beta 8 / \alpha v \beta 1$ integrin inhibitor PLN-101095

Poster 546
Presenter: Martin L. Decaris, Ph.D., Vice President, Translational Sciences, Pliant Therapeutics
Date: Saturday, November 7, 2026, 12:00 – 1:30 p.m. and 6:40 – 8:10 p.m. Mountain Time
Location: North Building - Lower Level - Exhibition Halls 4-6

FORTIFY - PLN-101095 Phase 1a/1b Indication Expansion Trial

PLN-101095 is currently being evaluated in a Phase 1a/1b open-label, dose-escalation and indication expansion trial ([NCT06270706](#)) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in the Phase 1b trial portion of FORTIFY consisting of three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant's lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of $\alpha v \beta 8$ and $\alpha v \beta 1$ integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1a/1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant's preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes as well as other cell types.

For additional information on Pliant, visit www.PliantRx.com and follow us on [X](#), [LinkedIn](#) and [Facebook](#).

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com